RareCyte signs CRADA with NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RARECYTE Inc. signed a Cooperative Research and Development Agreement with NCI for a three-year collaboration to investigate the use of RareCyte’s technology to identify, characterize, capture and analyze rare immune cell populations as well as individual circulating tumor cells derived from preclinical and clinical studies conducted by the NCI. The specific goals of the CRADA...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login